Sandbox:Sahar: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 97: Line 97:
clinical features.
clinical features.
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #FFFFFF;" align="center" |'''B'''
| style="padding: 5px 5px; background: #0000CD;" align="center" |'''B'''
|
|
|-
|-
Line 112: Line 112:
clinical probability.
clinical probability.
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''B'''
| style="padding: 5px 5px; background: #0000CD;" align="center" |'''B'''
|
|
|-
|-
Line 125: Line 125:
diagnosis.
diagnosis.
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''C'''
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
|
|
|-
|-
Line 138: Line 138:
tests should be considered.
tests should be considered.
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''B'''
| style="padding: 5px 5px; background: #0000CD;" align="center" |'''B'''
|
|
|-
|-
Line 149: Line 149:
recommended.
recommended.
| style="padding: 5px 5px; background: #F08080;" align="center" |'''III'''
| style="padding: 5px 5px; background: #F08080;" align="center" |'''III'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''C'''
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
|
|
|-
|-
Line 158: Line 158:
initial imaging investigation.
initial imaging investigation.
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
Line 176: Line 176:
!TOE
!TOE
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
!CT
!CT
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
Line 201: Line 201:
!CT
!CT
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
!MRI
!MRI
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
!TOE
!TOE
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIa'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
Line 224: Line 224:
recommended.
recommended.
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
Line 233: Line 233:
clinical probability of AAS.
clinical probability of AAS.
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIb'''
| style="padding: 5px 5px; background: #FFFACD;" align="center" |'''IIb'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|-
|-
Line 246: Line 246:
recommended.
recommended.
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
| style="padding: 5px 5px; background: #90EE90;" align="center" |'''I'''
!C
| style="padding: 5px 5px; background: #6495ED;" align="center" |'''C'''
!
!
|}
|}

Revision as of 04:06, 25 December 2019

Recomendacations Class Level References
History and clinical assessment
In all patients with suspected

AAS, pre-test probability

assessment is recommended,

according to the patient’s

condition, symptoms, and

clinical features.

I B
Laboratory testing
In case of suspicion of AAS,

the interpretation of

biomarkers should always be

considered along with the pretest

clinical probability.

IIa B
In case of low clinical

probability of AAS, negative D-dimer

levels should be

considered as ruling out the

diagnosis.

IIa C
In case of intermediate clinical

probability of AAS with a

positive (point-of-care) D-dimer

test, further imaging

tests should be considered.

IIa B
In patients with high probability

(risk score 2 or 3) of AD,

testing of D-dimers is not

recommended.

III C
Imaging
TTE is recommended as an

initial imaging investigation.

I C
In unstabled patients with a

suspicion of AAS, the following

imaging modalities are

recommended according to

local availability and expertise:

TOE I C
CT I C
In stable patients with a

suspicion of AAS, the

following imaging modalities

are recommended (or should

be considered) according to

local availability and expertise:

CT I C
MRI I C
TOE IIa C
In case of initially negative

imaging with the persistence of

suspicion of AAS, repetitive

imaging (CT or MRI) is

recommended.

I C
Chest X-ray maybe

considered in cases of low

clinical probability of AAS.

IIb C
In case of uncomplicated

Type B AD treated medically,

repeated imaging (CT or

MRI)e during the first days is

recommended.

I C